On Tuesday, Shares of Freeport-McMoRan Inc. (NYSE:FCX), surged 8.44% to $12.33.
Freeport-McMoRan declared it has undertaken a comprehensive review of its operating plans in its mining and oil and gas businesses to target noteworthy additional reductions in capital spending and operating and administrative costs in response to weak market conditions for its major products. These plans will also incorporate potential adjustments to mine plans and future copper and molybdenum production volumes to reduce costs and preserve valuable resources for anticipated improved market conditions in the future. The company anticipates to complete this review promptly and will report its revised plans during the third quarter of 2015.
Freeport-McMoRan Inc., a natural resource company, engages in the acquisition of mineral assets, and oil and natural gas resources. It primarily explores for copper, gold, molybdenum, cobalt, silver, and other metals, in addition to oil and gas. The company operates through North America Copper Mines; South America Mining; Indonesia Mining; Africa Mining; Molybdenum Mines; United States (U.S.) Oil and Gas Operations; Rod & Refining; and Atlantic Copper Smelting & Refining segments.
Shares of Boston Scientific Corporation (NYSE:BSX), inclined 2.34% to $17.51, during its last trading session.
Boston Scientific Corporation generated sales of $1.843 billion during the second quarter ended June 30, 2015, contrast to the company’s guidance range for the quarter of $1.800 to $1.850 billion. This represents 6 percent operational revenue growth (constant currency basis, not taking into account divested businesses) and a decrease of 2 percent on a stated basis, all contrast to the preceding year period. The company achieved adjusted earnings per share of $0.22 for the period, contrast to $0.21 a year ago, and GAAP earnings of $102 million, or about $0.08 per share, contrast to $0.00 a year ago.
Second quarter financial results and recent developments:
- Achieved second quarter sales of $1.843 billion, representing 6 percent operational revenue growth and a decrease of 2 percent on a stated basis, all contrast to the preceding year period.
- Delivered adjusted earnings per share of $0.22 contrast to the company’s guidance range of $0.20 to $0.22, and GAAP income of $0.08 per share contrast to the company’s guidance range of $0.09 to $0.11 per share.
- Stated second quarter revenue growth of 10 percent in Cardiovascular, 7 percent in MedSurg, and remained flat in Rhythm Administration, all on a constant currency basis over the preceding year period.
- Delivered strong operational revenue growth of 6 percent across all three major regions (U.S., Europe, and Asia, Middle East and Africa) and 12 percent operational revenue growth in the Emerging Markets.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with -0.55% loss, and closed at $5.41.
Exelixis declared recently that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis administration will host a conference call to talk about the results and provide a general business update. The conference call will be accessible via the Internet from the company’s website.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
